Back FINLAY-FR-2 Arabic Soberana 02 Catalan Soberana 02 Czech Soberana-2 German Soberana 02 Spanish سوبرانا ۰۲ Persian Soberana 02 French FINLAY-FR-2 ID Soberana 02 Italian FINLAY-FR-2 Japanese
 | |
 A vial of Soberana 02 | |
| Vaccine description | |
|---|---|
| Target | SARS-CoV-2 |
| Vaccine type | Conjugate |
| Clinical data | |
| Trade names | Pasteur |
| Other names | FINLAY-FR-2 Pasteurcovac, Pasto Covac, پاستوکووک |
| Routes of administration | Intramuscular |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| DrugBank | |
| Part of a series on the |
| COVID-19 pandemic |
|---|
 |
|
.svg){kind=small} COVID-19 portal |
Soberana 02 or Soberana 2, technical name FINLAY-FR-2, is a COVID-19 vaccine produced by the Finlay Institute, a Cuban epidemiological research institute. The vaccine is known as PastoCovac (Persian: پاستوکووک) in Iran, where it has been developed in collaboration with the Pasteur Institute of Iran.[2][3][4]
It is a conjugate vaccine that requires two doses, the second one being administered 28 days after the first shot.[5] A third (booster) dose of Soberana Plus may also be given on day 56. It has received emergency use authorization in Iran in June 2021, and in Cuba in August 2021, where it has also been approved for children above 2 years old.[6]
The name of the vaccine, Soberana, is a Spanish word that means "sovereign".[7] It followed a previous candidate vaccine called SOBERANA-01 (FINLAY-FR-1).[8]
- ^ "Patent Landscape Report COVID-19-related vaccines and therapeutics" (PDF).
- ^ Mallapaty S (August 2021). "Iran hopes to defeat COVID with home-grown crop of vaccines". Nature. 596 (7873): 475. Bibcode:2021Natur.596..475M. doi:10.1038/d41586-021-02216-z. PMID 34404947. S2CID 237198729.
- ^ "PasteurCovac". Pasteur Institute of Iran. Archived from the original on 17 January 2022. Retrieved 31 January 2022.
- ^ "Iran-Cuba vaccine enters phase three clinical trials". Tehran Times. 26 April 2021. Retrieved 7 September 2021.
- ^ Gorry C (October 2020). "SOBERANA, Cuba's COVID-19 Vaccine Candidates: Dagmar García-Rivera PhD". MEDICC Review. 22 (4): 10–15. doi:10.37757/mr2020.v22.n4.11. PMID 33295312. S2CID 228079254.
- ^ Hotez PJ, Bottazzi ME (January 2022). "Whole Inactivated Virus and Protein-Based COVID-19 Vaccines". Annual Review of Medicine. 73 (1): 55–64. doi:10.1146/annurev-med-042420-113212. PMID 34637324. S2CID 238747462.
- ^ Rasmussen SE, Eqbali A (12 January 2021). "Iran, Cuba, Under U.S. Sanctions, Team Up for Covid-19 Vaccine Trials". The Wall Street Journal.
- ^ Cite error: The named reference
:0was invoked but never defined (see the help page).